Ischemia modified albumin in experimental ovarian torsion with and without controlled reperfusion

Open access


Purpose: Ovarian torsion, being a gynecological emergency, requires to be rapidly diagnosed and treated with minimal consequences on ovarian function after the removal of torsion. As ischemia modified albumin (IMA) is considered a good biomarker in diverse ischemic diseases, the aim of our study was to determine the effect of different ovarian torsion/detorsion models on serum and ovarian homogenates levels of IMA in an experimental study.

Methods: IMA was measured in the serum and ovarian homogenates of 7 groups of female rats (10 animals in each group): 1 - control (no intervention); 2 - sham (only laparotomy); 3 - ischemia group: 3 hours ovarian torsion (OT); 4 - 3 hours OT (ischemia), 1 hour simple reperfusion; 5 - 3 hours ischemia, 1 hour controlled reperfusion that was assured during the first two minutes by opening and closing the clips on the ovarian pedicles in 10 seconds intervals, followed by simple reperfusion; 6 - 3 hours ischemia, 24 hours simple reperfusion; 7 - 3 hours OT, 24 hours controlled reperfusion. The results were analyzed by Welch’s ANOVA and Spearman correlation.

Results: Ischemia increases the IMA in both serum and ovarian homogenates compared to control and sham groups. The controlled reperfusion groups had a statistically significant lower IMA in serum compared to simple reperfusion groups. IMA was found to be higher in the ovarian homogenates of simple reperfusion compared to controlled reperfusion groups.

Conclusion: Our results suggest that controlled reperfusion prevent the processes that increase the IMA in ovarian torsion.

1. McCloskey K, Grover S, VuillerminBabl FE. Ovarian torsion among girls presenting with abdominal pain: a retrospective cohort study. Emerg Med J. 2013; 30(1):e11. DOI: 10.1136/emermed-2011-200200

2. Karatas Gurgun A, Kaban I, Aka N, Mentese A, Aker F, Uras AR. The Role of ischemia Modified Albumin and D-dimer as Early or Late Biochemical Markers in Ovarian Torsion. J Obstet Gynaecol Res. 2017; 43(5):895-901. DOI: 10.1111/jog.13281

3. Tuncer AA, Bozkurt MF, Koken T, Dogan N, Pektaş MK, Baskin Embleton D. The Protective Effects of Alpha-Lipoic Acid and Coenzyme Q10 Combination on Ovarian Ischemia-Reperfusion Injury: An Experimental Study. Adv Med. 2016; 2016:3415046. DOI: 10.1155/2016/3415046

4. Zucchini S, Marra E. Diagnosis of emergencies/urgencies in gynecology and during the first trimester of pregnancy. J Ultrasound. 2014; 17(1):41-6. DOI: 10.1007/s40477-013-0059-0

5. Childress KJ, Dietrich JE. Pediatric ovarian torsion. Surg Clin North Am. 2017; 97(1):209-21. DOI: 10.1016/j.suc.2016.08.008

6. Spinelli C, Piscioneri J, Strambi S. Adnexal torsion in adolescents: update and review of the literature. Curr Opin Obstet Gynecol. 2015; 27(5):320-5. DOI: 10.1097/GCO.0000000000000197

7. Karaman E, Beger B, Çetin O, Melek M, Karaman Y. Ovarian Torsion in the Normal Ovary: A Diagnostic Challenge in Postmenarchal Adolescent Girls in the Emergency Department. Med Sci Monit. 2017; 23:1312-6. DOI: 10.12659/MSM.902099

8. BolliSchädelin S, Holland-Cunz S, ZimmermannOvarian torsion in children: Development of a predictive score. Medicine. 2017; 96(43):e8299. DOI: 10.1097/MD.0000000000008299

9. Aran T, Guven S, Unsal MA, Alver A, Mentese A, Yulug E. Serum ischemia-modified albumin as a novel marker of ovarian torsion: an experimental study. Eur J Obstet Gynecol Reprod Biol. 2010; 150(1):72-5. DOI: 10.1016/j.ejogrb.2010.01.006

10. Guven S, Kart C, Guven ESG, Cetin EC, Menteşe A. Is the measurement of serum ischemia-modified albumin the best test to diagnose ovarian torsion? Gynecol Obstet Invest. 2015; 79(4):269-75. DOI: 10.1159/000367787

11. Laganà AS, Sofo V, Salmeri FM, Palmara VI, Triolo O, Terzić MM, et al. Oxidative stress during ovarian torsion in pediatric and adolescent patients: changing the perspective of the disease. Int J Fertil Steril. 2016; 9(4):416-23.

12. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell Biology of Ischemia/Reperfusion Injury. Int Rev Cell Mol Biol. 2012; 298:229–317. DOI: 10.1016/B978-0-12-394309-5.00006-7

13. Żurawska-Płaksej E, Grzebyk E, Marciniak D, Szymańska-Chabowska A, Piwowar A. Oxidatively modified forms of albumin in patients with risk factors of metabolic syndrome. J Endocrinol Invest. 2014; 37(9):819-27. DOI: 10.1007/s40618-014-0111-8

14. Mertoglu C, Gunay M, Gurel A, Gungor M, Gul V. Ischemic modified albumin increases in acute kidney injury. Rev Romana Med Lab. 2018; 26(1):37-43. DOI: 10.2478/rrlm-2018-0002

15. Shen XL, Lin CJ, Han LL, Lin L, Pan L,XD. Assessment of ischemia-modified albumin levels for emergency room diagnosis of acute coronary syndrome. Int J Cardiol. 2011; 149(3):296-8. DOI: 10.1016/j.ij-card.2010.01.013

16. Gaze DC. Ischemia Modified Albumin: a novel bio-marker for the detection of cardiac ischemia. Drug Metab Pharmacokinet. 2009; 24(4):333-41. DOI: 10.2133/dmpk.24.333

17. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocar-dial ischemia. Eur J Biochem. 2001; 268(1):42-7. DOI: 10.1046/j.1432-1327.2001.01846.x

18. Liyan C, Jie Z, Yonghua W, Xiaozhou H. Assay of ischemia-modified albumin and c-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal. 2008; 22(1):45-9. DOI: 10.1002/jcla.20223

19. Yildirim A, Yildirim S, Topaloglu N, Tekin M, Kucuk A, Erdem H, et al. Correlation of ischemia-modified albumin levels and histopathologic findings in experimental ovarian torsion. Turk J Emerg Med. 2016; 16(1):8-11. DOI: 10.1016/j.tjem.2016.02.004

20. Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol. 2006; 108(3):410-11. DOI: 10.1016/j.ijcard.2005.03.040

21. Marx G, Chevion M. Site-specific modification of albumin by free radicals. Reaction with copper (II) and ascorbate. Biochem J. 1986; 236(2):397-400. DOI: 10.1042/bj2360397

22. Gudumac V, Tagadiuc O. Metodă de determinare a capacității albuminei ischemic modificate de legare a cobaltului. Brevet de invenție nr. MD 4054 din 11.06.2009

23. Ingec M, Isaoglu U, Yilmaz M, Calik M, Polat B, Alp HH, et al. Prevention of ischemia-reperfusion injury in rat ovarian tissue with the on-off method. J Physiol Pharmacol. 2011; 62(5):575-82.

24. Ozkisacik S, Yazici M, Gursoy H, Culhaci N. Does gradual detorsion protect the ovary against ischemia-reperfusion injury in rats? Pediatr Surg Int. 2014; 30(4):437-40. DOI: 10.1007/s00383-014-3480-3

25. Gencer M, Karaca T, Güngör AN, Hacıvelioğlu SÖ, Demirtaş S, Turkon H, et al. The protective effect of quercetin on IMA levels and apoptosis in experimental ovarian ischemia-reperfusion injury. Eur J Obstet Gynecol Reprod Biol. 2014; 177:135-40. DOI: 10.1016/j.ejogrb.2014.03.036

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information

IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 169 169 29
PDF Downloads 85 85 14